Orthopediatrics (KIDS) reported $236M in revenue for fiscal 2025, +15.4% year on year. That ranks #2603 by revenue among 2853 SEC filers and #270 in Healthcare. It posted a net loss of −$39.6M for the same year. Revenue has grown 22.5% a year on average since 2015 ($31.0M then). The fiscal 2025 balance sheet shows $509M in total assets, $19.6M in cash and $99.8M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $236M | +15.4% | FY20252025-12-31 |
| Gross profitGrossProfit | $173M | +16.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$39.2M | −$4.2M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$39.6M | −$1.8M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$4.9M | +$22.2M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $11.1M | −22.1% | FY20252025-12-31 |
| Total assetsAssets | $509M | +7.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $347M | −2.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $19.6M | −55.4% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $99.8M | +36.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $59.4M | −$10.7M | Open → |
| Q2 20262026-06-30 | $70.5M | −$7.2M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Orthopediatrics Corp
- Ticker
- KIDS
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001425450
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 1, 2026Open filing →
- 10-KMar 4, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Keros TherapeuticsKROS | $244M | $87.0M |
| Staar SurgicalSTAA | $239M | −$80.4M |
| VaxartVXRT | $237M | $16,327 |
| OrthopediatricsKIDS | $236M | −$39.6M |
| Akebia TherapeuticsAKBA | $236M | −$5.3M |
| AnaptysbioANAB | $235M | −$13.2M |
| CerusCERS | $234M | −$15.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Orthopediatrics — Key figures |url=https://companiesranked.com/en/company/orthopediatrics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Orthopediatrics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/orthopediatricsBibTeX
@misc{companiesranked-en-company-orthopediatrics-2026,
author = {{CompaniesRanked}},
title = {{Orthopediatrics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/orthopediatrics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001425450-26-000013 · March 4, 2026
{{cite web |title=Orthopediatrics — Key figures — 10-K (0001425450-26-000013) |url=https://www.sec.gov/Archives/edgar/data/1425450/000142545026000013/kids-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-04}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.